The nanocarrier-based delivery system has emerged as a promising candidate for cancer therapy; nevertheless, their quality problems, variation between batches, and carrier-related toxicity issues have restricted their clinical utilization. Compared with traditional carrier-based nanoparticles, carrier-free nanodrug delivery systems preferred to overcome all these drawbacks and will have a wide range of applications in biomedicine and nanotechnology. Herein, we developed a novel carrier-free nanodrug Asp-UA consisted of the classical drug aspirin and the natural plant drug UA via a green and simple approach. The Asp-UA NPs were investigated for shape, particle size, zeta potential, stability, and UV–vis spectroscopy absorption. Cellular uptake study showed that Asp-UA NPs could be easily internalized by HepG2 cells; cellular study demonstrated that Asp-UA NPs held better inhibitory efficiency on tumor metastasis with low toxicity in vitro and in vivo. Moreover, Asp-UA NPs could obviously suppress the progress of cancer metastasis by H22 cells in vivo. Overall, Asp-UA NPs possess a variety of advantages and hold promise to become an alternative to the treatment of cancer metastasis.

中文翻译：

---

小分子纳米药物组装的双重抗癌药物共轭转移癌治疗。

基于纳米载体的递送系统已经成为癌症治疗的有希望的候选者。但是，它们的质量问题，批次之间的差异以及与载体相关的毒性问题限制了它们的临床应用。与传统的基于载体的纳米颗粒相比，无载体的纳米药物递送系统更能克服所有这些缺点，并将在生物医学和纳米技术中具有广泛的应用。在本文中，我们通过绿色简单的方法开发了由经典药物阿司匹林和天然植物药物UA组成的新型无载体纳米药物Asp-UA。研究了Asp-UA NP的形状，粒度，ζ电位，稳定性和UV-vis光谱吸收。细胞摄取研究表明，HepG2细胞很容易将Asp-UA NP内在化。体外和体内。而且，Asp-UA NPs可以明显抑制H22细胞在体内转移癌症的进程。总体而言，Asp-UA NP具有多种优势，有望成为癌症转移治疗的替代方法。